In January 2024, Allakos announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the company’s cash runway is expected to extend into mid-2026. Allakos will halt lirentelimab-related activities across clinical, manufacturing, research and administrative functions, resulting in a layoff of half od its workforce. As a result, the company will reduce its workforce by approximately 50%.